Our analysis of publicly available datasets shows that SKP2 gene is frequently amplified in multiple cancers, including sarcoma, urothelial cancer, and prostate cancer, and that higher SKP2 mRNA levels in prostate tumor tissues are associated with poorer overall survival of prostate cancer patients. Here, SKP2 is linked to prostate carcinoma.